Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations
- 1 February 2024
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (2) , 278-290
Abstract
PURPOSE: We evaluated the potential cost-effectiveness of combined magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS) screening for pancreatic ductal adenocarcinoma (PDAC) among populations at high risk for the disease. METHODS: We used a microsimulation model of the natural history of PDAC to estimate the lifetime health benefits, costs, and cost-effectiveness of PDAC screening among populations with specific genetic risk factors for PDAC, including BRCA1 and BRCA2, PALB2, ATM, Lynch syndrome, TP53, CDKN2A, and STK11. For each high-risk population, we simulated 29 screening strategies, defined by starting age and frequency. Screening included MRI with follow-up EUS in a subset of patients. Costs of tests were based on Medicare reimbursement for MRI, EUS, fine-needle aspiration biopsy, and pancreatectomy. Cancer-related cost by stage of disease and phase of treatment was based on the literature. For each high-risk population, we performed an incremental cost-effectiveness analysis, assuming a willingness-to-pay (WTP) threshold of $100,000 US dollars (USD) per quality-adjusted life year (QALY) gained. RESULTS: For men with relative risk (RR) 12.33 ( CDKN2A) and RR 28 ( STK11), annual screening was cost-effective, starting at age 55 and 40 years, respectively. For women, screening was only cost-effective for those with RR 28 ( STK11), with annual screening starting at age 45 years. CONCLUSION: Combined MRI/EUS screening may be a cost-effective approach for the highest-risk populations (among mutations considered, those with RR >12). However, for those with moderate risk (RR, 5-12), screening would only be cost-effective at higher WTP thresholds (eg, $200K USD/QALY) or with once-only screening.Keywords
This publication has 76 references indexed in Scilit:
- Frequent Detection of Pancreatic Lesions in Asymptomatic High-Risk IndividualsGastroenterology, 2012
- Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)Journal of Pain and Symptom Management, 2012
- Trends in Hospital Volume and Operative Mortality for High-Risk SurgeryNew England Journal of Medicine, 2011
- Feasibility and Yield of Screening in Relatives From Familial Pancreatic Cancer FamiliesAmerican Journal of Gastroenterology, 2011
- Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counselingEuropean Journal of Human Genetics, 2010
- TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypesJournal of Medical Genetics, 2010
- BRCA Germline Mutations in Jewish Patients With Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2009
- Prevalence of Unsuspected Pancreatic Cysts on MDCTAmerican Journal of Roentgenology, 2008
- Pancreatic cancer and the FAMMM syndromeFamilial Cancer, 2007
- An update on familial pancreatic cancer and the management of asymptomatic relativesHPB, 2007